Table 3.
Intra-individual stability of an eGFR decline ≥ 5 ml/min/1.73m2/year over time.
| eGFR decline ≥ 5 ml/min/1.73m2/year until | ||||
|---|---|---|---|---|
| 2nd year of FU | 3rd year of FU | 4th year of FU | 5th year of FU | |
| PROVALID (n = 860) | ||||
| FU2 (n/%) | 288 (100) | 169 (58.7) | 112 (38.9) | 79 (27.4) |
| FU3 (n/%) | 169 (82.0) | 206 (100) | 119 (57.8) | 80 (38.8) |
| FU4 (n/%) | 112 (76.2) | 119 (81.0) | 147 (100) | 87 (59.2) |
| FU5 (n/%) | 79 (74.5) | 80 (75.5) | 87 (82.1) | 106 (100) |
| Validation cohort (n = 178) | ||||
| FU2 (n/%) | 46 (100) | 19 (41.3) | 12 (26.1) | 10 (21.7) |
| FU3 (n/%) | 19 (79.2) | 24 (100) | 13 (54.2) | 10 (41.7) |
| FU4 (n/%) | 12 (63.2) | 13 (68.4) | 19 (100) | 15 (78.9) |
| FU5 (n/%) | 10 (55.6) | 10 (55.6) | 15 (83.3) | 18 (100) |
FU follow up.
Bold numbers: number of individuals (%) persistently meeting the definition of eGFR decline over time. The calculation of the slopes is based on linear regressions using at least 3 eGFR observations for each patient. For this reason, a comparison between baseline and FU1 is missing in the table.